Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2003

View Archived Issues

Completion of phase I study of vaccinia immune globulin

Screening commences for phase II study of Prosaptide

Advanced Biotherapy to study antibody therapy in organ transplant rejection

Roche presents novel DPP-IV inhibitors in a recent patent

New HIV protease inhibitors prepared and tested at Tibotec-Virco

Lundbeck claims glycine transport inhibitors and their use in psychosis, cognition disorders, etc.

Novel PDE7 inhibitors and their use reported by Daiichi Suntory and Suntory scientists

HNE inhibitors with potential in COPD therapy covered by Bayer patent

Bayer researchers design adenosine A1 receptor agonists for ischemic disorders

New mGluR1 antagonists in early development at Bayer

Two series of adenosine A3 receptor antagonists described by Sanofi-Synthelabo

Analgesic effects reported for KRN-5500 in a murine model of neuropathic pain

Potential use of interferon in the therapy of SARS

Priority review for diquafosol tetrasodium NDA

Bexxar launched in U.S.

Small-molecule Bcl-2 inhibitor with apoptosis-inducing effects in cancer cells

Cytogen completes reacquisition of Quadramet marketing rights

Evotec Neurosciences and Takeda form Alzheimer's collaboration

Maxim discusses discovery and development of apoptosis inducers at cancer meeting

Enbrel approved to improve physical function in RA patients

FDA approves Zavesca for type 1 Gaucher's disease

Japan Tobacco to commercialize Gilead HIV products in Japan

FDA advisory committee sets review date for Raptiva

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.